In recent years, point-of-care-testing (POCT) has become a popular vocabulary in laboratory medicine and clinical fields. It first appeared in the United States, meaning that diagnosis, monitoring, and treatment are performed at the location of the disease or incident, and the test results can be obtained quickly and the correct treatment can be made in time. The development of POCT has led to an increasing demand for compact optics and inspection technology. Disease inspections are usually carried out in the central laboratory of the hospital. Although the cost of a single item of inspection is low, the test results cannot be obtained in time, and targeted treatment cannot be started immediately. At the same time, it is also restricted by the test site. The emergence of POCT can be said to fill the gap of rapid diagnosis.

Today, the scope of POCT inspection is expanding. The inspection of certain items has gone from obtaining qualitative results to obtaining quantitative parameters. The accuracy and reliability of the results are not only comparable to those of the central laboratory, but also non-professionals can also operate. With the advantages of small capacity and rapid growth, and broad prospects, the POCT market, as an effective supplement to large-scale central laboratory testing, has achieved tremendous development and has a place in the field of laboratory medicine today.

Desheng chemiluminescence reagent

The biochemical reagent industry seems to have few opportunities, but it actually cultivates good opportunities. Clinical biochemical 200 manufacturers, as the CFDA strengthens supervision, excellent domestic brands will accelerate the integration of market share and maintain a growth rate that surpasses the broader market. At present, the outstanding biochemical technology companies include Desheng Biochemical Technology. Manufacturers of chemiluminescence reagents are in the ascendant, with promising prospects. As a market segment with both high capacity growth rates, domestic substitution has just begun. Chemiluminescence is the largest segment of domestic IVD. With the increase of chemiluminescence instruments, the demand for chemiluminescence reagents has increased, and acridine esters are the mainstream chemiluminescence. The reagents can detect a variety of items, basically covering the main test items of the laboratory, such as infectious diseases and tumors.

Based on industrial research, the decline in the growth rate of the in vitro diagnostic industry does not mean that the growth rate of outstanding domestic companies has continued to slow down. Since mid-2014, the CFDA has successively introduced a series of policies to strengthen industry supervision and raise the barriers to entry. We believe that the first year of industry turbulence and integration has begun. In the context of hierarchical diagnosis and treatment and medical reform, strict regulatory requirements and the vigorous promotion of the national import substitution policy, the effective rectification of non-standard small enterprises in the industry has inhibited the strong monopoly of imported brands. The change of the macro environment is like a spring breeze. The rise of domestic brands is just around the corner, and there are still good opportunities for domestic brands.

Desheng Biochemical Technology is one of the favorable risers among domestic brands. Desheng has a strict quality control system, a perfect inventory supply system, a professional sales team and a technical service team, and a good market reputation. The R&D and production experience of in-vitro diagnostic reagents has won unanimous praise from users and manufacturers at home and abroad. The in-vitro diagnostic reagents currently developed and produced include blood collection tube additives, chemiluminescence reagents, color reagents, biological buffers and other products. Welcome to negotiate communicate with.